Navigation Links
Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:11/3/2008

nine months."

According to Dr. Lesley Russell, Executive Vice President and Chief Medical Officer, Cephalon, "We are excited about this second FDA approval for TREANDA in 2008. This approval of TREANDA for indolent non-Hodgkin's lymphoma is a significant milestone in our development of a diverse oncology portfolio of products that improve patient outcomes."

The FDA approval is supported by a pivotal trial of 100 patients with indolent B-cell NHL who had progressed during or within six months of treatment with a regimen that included rituximab. The pivotal study demonstrated that patients had a high response rate to treatment with TREANDA, and these responses to the treatment were durable. The results from the pivotal study showed that treatment with Treanda as a single agent resulted in an overall response rate of 74 percent, which means that after treatment, the cancer diminished or disappeared in approximately three out of four patients. Additionally, patient response to treatment in the pivotal study lasted a median of 9.2 months and patients remained alive and their disease did not progress for a median of 9.3 months.

The safety of TREANDA is also supported by a secondary monotherapy study. In the pivotal and secondary studies for TREANDA in indolent NHL, the most common non-hematologic adverse reactions (frequency greater than or equal to;15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decrease, dyspnea, rash and stomatitis. The most common hematologic abnormalities (frequency greater than or equal to;15%) are lymphopenia, leukopenia, anemia, thrombocytopenia and neutropenia.

In addition to its proven efficacy and tolerable side effect profile, TREANDA has a convenient dosing schedule as a treatment for indolent NHL. An intravenous infusion takes 60 minutes and can be administered in an outpatient setting, reducing the time it takes for patients to be treated. The recommended dos
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The North America Sports Drink Market report ... with analysis and forecast of revenue. The Sports Drink Market ... million in 2012 to $6,243 million by 2018, at a ... the TOC of the North America Sports Drink market report, ... also provides a glimpse of the segmentation in the North ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... of aging has chosen Carole B. Lewis, PT, ... 2014 recipient of the Excellence in Rehabilitation of Aging ... to acknowledge outstanding contributions in the field of rehabilitation. ... teaching or patient care, or publications that may include ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... York City, NY (PRWEB) August 01, 2014 ... for two incomes, and the convenience of processed, microwavable dinners, ... epidemic. Diet Doc does not offer patients a mere quick ... about helping everyone, in any part of the country, get ... that if they offer patients the tools and education on ...
(Date:8/1/2014)... This week marks a significant milestone for ... of paying commissions to its independent distributor sales force. ... 2005 total $1,405,954,677.06. , MonaVie distributors can be found ... commissions in 18 different currencies, including: AUD, EUR, BRL, ... USD, SGD, KRW, TWD, THB and GBP. , ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... of Chemistry at Stevens Institute of Technology, recently ... of Michigan. Named in honor of pioneer pharmaceutical ... established to recognize outstanding lifetime achievements in medicinal ... lecture, "Drug Discovery Lessons Learned," was delivered ...
... News) -- Early adolescence is the time that patients with ... pediatric to adult medical care, says a new American Heart ... birth, is the most common type of birth defect. Most ... The majority of children born with a congenital heart ...
... lab tests and imaging can sometimes help diagnose juvenile ... history are the most valuable tools in identifying this ... Journal of the American Academy of Orthopaedic Surgeons ... evaluations and imaging studies meant to screen for juvenile ...
... Turmeric, a bright yellow spice from south Asia belonging ... curries and ancient wisdom suggests that it,s also ... laboratory, Tel Aviv University researchers have discovered that turmeric,s ... highly toxic anti-inflammatory drugs used to fight colon cancer ...
... Amanda Gardner HealthDay Reporter , TUESDAY, March ... or young adult raises your risk of having psychotic ... "This cements much more firmly the reality that ... with the other genetic, environmental and socioeconomic risk factors, ...
... March 2 (HealthDay News) -- A daytime nap of at least ... protect their heart, a new study suggests. The finding comes ... two groups. One group had an hour-long period during the day ... groups were given a mental stress test. Blood pressure and ...
Cached Medicine News:Health News:Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan 2Health News:Teens With Congenital Heart Disease Need Help Moving to Adult Care 2Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Fighting cancer at your local Indian restaurant 2Health News:Pot Use in Youth Ups Risk of Psychotic Symptoms in Later Life 2
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... and VIENNA , July 31, 2014 ... press conference in New York results ... vaccine against Parkinson,s disease. PD01A is the first therapy against ... clinical testing. The Michael J. Fox Foundation for ... million grant, and presented at the press conference on the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
Standard Deflectable Catheters...
Fixed and steerable lumen diagnostic mapping catheters are offered in a variety of catheter configurations...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
Sophisticated DecaPolar Catheters provide enhanced recording and mapping quality....
Medicine Products: